Perspective Therapeutics, Inc. (NYSE:CATX) Given Average Recommendation of “Buy” by Brokerages

Perspective Therapeutics, Inc. (NYSE:CATX) has been assigned an average recommendation of “Buy” from the ten research firms that are presently covering the company, Marketbeat Ratings reports. Ten analysts have rated the stock with a buy rating. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $20.63.

Several research analysts have recently weighed in on the stock. Truist Financial started coverage on shares of Perspective Therapeutics in a research note on Wednesday, September 25th. They set a “buy” rating and a $21.00 price objective on the stock. Oppenheimer restated an “outperform” rating and issued a $22.00 price objective on shares of Perspective Therapeutics in a research note on Friday, October 11th. Bank of America assumed coverage on Perspective Therapeutics in a research report on Thursday, July 25th. They issued a “buy” rating and a $24.00 price objective for the company. Royal Bank of Canada dropped their price target on Perspective Therapeutics from $29.00 to $27.00 and set an “outperform” rating on the stock in a research note on Friday, August 16th. Finally, Wedbush reaffirmed an “outperform” rating and set a $20.00 price target on shares of Perspective Therapeutics in a report on Thursday, October 24th.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Intech Investment Management LLC bought a new stake in shares of Perspective Therapeutics in the third quarter valued at about $137,000. LMR Partners LLP acquired a new stake in Perspective Therapeutics in the 3rd quarter worth about $400,000. RIA Advisory Group LLC bought a new stake in Perspective Therapeutics in the 3rd quarter valued at about $342,000. CIBC Asset Management Inc acquired a new position in shares of Perspective Therapeutics during the 3rd quarter worth approximately $259,000. Finally, Victory Capital Management Inc. increased its holdings in shares of Perspective Therapeutics by 328.7% during the third quarter. Victory Capital Management Inc. now owns 50,460 shares of the company’s stock worth $674,000 after purchasing an additional 38,690 shares during the period. 54.66% of the stock is owned by institutional investors and hedge funds.

Perspective Therapeutics Trading Down 4.5 %

NYSE:CATX opened at $11.25 on Tuesday. Perspective Therapeutics has a twelve month low of $2.20 and a twelve month high of $19.05. The business’s 50 day moving average is $13.09.

Perspective Therapeutics (NYSE:CATX) last released its earnings results on Monday, August 12th. The company reported ($0.17) earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.04. The firm had revenue of $0.53 million during the quarter. Research analysts forecast that Perspective Therapeutics will post -0.87 EPS for the current fiscal year.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.